Novartis gets CDSCO panel nod to study anticancer drug JDQ443
New Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the study of the anti-cancer JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor.However, the approval is subject to a condition that the firm should update safety and...
New Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the study of the anti-cancer JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor.
KRAS mutations are the most frequent oncogenic drivers in non-small cell lung cancer (NSCLC), the most common type of lung cancer. The most common form of KRAS mutation is G12C4. JDQ443 inhibits this mutated form of KRAS in a structurally distinct way, trapping KRAS G12C in a GDP-bound, inactive state while avoiding direct interaction with H95, a recognized route for resistance. In preclinical models, JDQ443 potently inhibited KRAS G12C cellular signalling and proliferation in a mutant-selective manner and demonstrated dose-dependent antitumor activity
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd